filovirus
ebola
viru
ebov
marburg
viru
marv
among
pathogen
virus
known
man
caus
agent
viral
hemorrhag
fever
outbreak
africa
case
fatal
rate
nearli
infect
observ
latest
ebov
epidem
west
africa
previou
outbreak
much
smaller
typic
affect
less
hundr
peopl
compar
diseas
aid
malaria
million
case
annual
filoviru
hemorrhag
fever
fhf
one
neglect
infecti
diseas
licens
vaccin
therapeut
avail
treat
ebov
marv
infect
therefor
pathogen
handl
maximum
contain
laboratori
classifi
select
agent
limit
laboratori
worldwid
conduct
basic
research
countermeasur
develop
ebov
marv
sinc
respect
discoveri
marv
ebov
review
discuss
sever
vaccin
platform
ebov
marv
assess
protect
efficaci
anim
model
fhf
focu
promis
approach
acceler
clinic
develop
phase
iiii
trial
ebov
epidem
west
africa
discoveri
two
negativestrand
rna
virus
marburg
viru
marv
ebola
viru
ebov
respect
mark
begin
era
marburg
ebola
hemorrhag
fever
outbreak
mhf
ehf
respect
africa
human
nonhuman
primat
virus
member
filovirida
famili
order
mononegaviral
classifi
categori
pathogen
select
agent
licens
vaccin
treatment
avail
human
use
pathogen
handl
maximum
contain
laboratori
imped
research
countermeasur
develop
ebolaviru
compos
five
known
speci
zair
ebolaviru
sudan
ebolaviru
forest
ebolaviru
bundibugyo
ebolaviru
reston
ebolaviru
known
caus
diseas
case
fatal
rate
contrast
one
speci
discov
within
genu
marburgviru
marburg
marburgviru
sinc
initi
discoveri
marburg
germani
repres
marburg
viru
marv
ravn
viru
ravv
sever
laboratori
worker
present
flulik
symptom
later
develop
sever
hf
caus
sever
infect
individu
die
despit
year
filoviru
research
licens
vaccin
postexposur
treatment
exist
either
deadli
virus
sever
vaccin
strategi
develop
offer
complet
protect
lethal
challeng
either
ebov
marv
nonhuman
primat
nhp
rodent
model
rodent
model
provid
insight
efficaci
filoviru
vaccin
gold
standard
model
ehf
mhf
rhesu
cynomolgu
macaqu
macaqu
model
display
major
diseas
hallmark
human
ehf
mhf
cadvaxebov
ebov
sudv
ebov
ebov
adcagoptzgp
adifna
ebov
ebov
mvabnfilo
ebov
adcagoptzgp
ebov
rec
inact
adjuv
ebov
ebov
rec
vesicular
stomat
viru
vsvebov
ebov
vsvebov
vsvsudv
vsvmarv
ebov
sudv
tafv
vsvebov
ebov
vesiculovaxrvsvebov
gp
ebov
vesiculovaxrvsvebov
gp
ebov
time
challeng
vaccin
complet
rodent
model
offer
limit
consid
invalu
resourc
macaqu
model
provid
surrog
human
ehf
mhf
experiment
vaccin
strategi
analyz
nonhuman
primat
model
focu
review
tabl
unless
otherwis
specifi
nhp
alway
challeng
ebov
marv
homolog
vaccineexpress
antigen
vaccin
platform
report
efficaci
rodent
model
mous
guinea
pig
hamster
list
tabl
close
review
inactiv
viru
subunit
vaccin
first
vaccin
platform
explor
ebov
publish
use
heatand
formalininactiv
wholeviru
particl
ebov
isol
inactiv
method
result
protect
guinea
pig
lethal
challeng
howev
anoth
studi
use
gammairradi
inactiv
viral
particl
without
liposom
encapsul
unsuccess
provid
protect
nhp
addit
convent
method
inactiv
treatment
photoinduc
alkyl
probe
ina
shown
similar
success
ebov
rodent
model
evalu
nhp
similarli
success
protect
guinea
pig
irradi
whole
marv
strain
musok
ravv
demonstr
limit
data
shown
efficaci
nhp
inactiv
viru
vaccin
platform
promis
data
inactiv
wholeviru
vaccin
report
filoviru
rodent
model
limit
immunogen
nhp
vaccin
strategi
justifi
nhp
studi
limit
data
describ
use
subunit
vaccin
produc
recombin
baculoviru
system
publish
experiment
data
determin
efficaci
marv
musok
glycoprotein
gp
variant
lack
transmembran
domain
gpdtm
produc
recombin
baculoviru
use
determin
efficaci
guinea
pig
guinea
pig
vaccin
lgdose
gpdtm
lethal
challeng
either
marv
musok
ravv
guinea
pig
surviv
respect
limit
efficaci
protect
mhf
subunit
baculoviru
vaccin
develop
recent
extracellular
domain
ebov
gp
fuse
fc
fragment
human
test
mice
guinea
pig
protect
lethal
challeng
vaccin
show
partial
protect
mice
guinea
pig
immun
vaccin
plu
adjuv
protect
could
observ
anoth
group
report
protect
efficaci
ebov
gp
adjuv
gp
combin
adjuv
mice
promis
result
safe
easytoproduc
vaccin
strategi
hope
efficaci
soon
evalu
ebov
nhp
model
promis
vaccin
strategi
recent
develop
halfmann
marzi
colleagu
use
replicationincompet
whole
ebov
vaccin
complet
protect
mice
guinea
pig
cynomolgu
macaqu
ebov
challeng
vaccin
replicationincompet
nearli
wholeviru
vaccin
deriv
mayinga
strain
ebov
code
region
viral
transcript
activ
delet
recombin
viru
abl
replic
cell
express
render
viru
unabl
propag
absenc
despit
convinc
data
show
recombin
event
mutat
surround
region
seven
serial
passag
cell
inabl
replic
regular
cell
express
rodent
still
concern
vaccin
safeti
address
apprehens
particl
subject
hydrogen
peroxid
h
inactiv
h
shown
success
inactiv
infect
retain
antigen
sever
virus
vaccinia
viru
influenza
viru
west
nile
viru
lymphocyt
choriomening
shown
complet
inactiv
method
confirm
plaqu
assay
cell
vaccin
abl
fulli
protect
cynomolgu
macaqu
lethal
challeng
administ
primeboost
vaccin
use
focusform
unit
ffu
week
apart
h
inactiv
group
one
administr
ffu
given
nhp
protect
lethal
challeng
achiev
yet
viremia
clinic
sign
ill
fever
observ
nearli
wholeviru
vaccin
offer
interest
approach
vaccin
ebov
viral
rna
major
viral
protein
except
present
contribut
complet
ebovspecif
immun
respons
retent
antigen
h
inactiv
addit
replic
defici
allow
manufactur
condit
addit
benefit
platform
yet
attract
product
viruslik
particl
vlp
assess
immun
approach
ebov
marv
vlp
offer
homolog
protect
nonhuman
primat
select
studi
produc
broad
protect
sever
strain
marv
ebov
marv
vlp
produc
express
two
viral
gene
matrix
protein
well
respect
gp
either
mammalian
insect
cell
marburg
musok
vlp
mvlp
abl
provid
protect
three
strain
marv
marv
musok
marv
ravv
rodent
nhp
advanc
version
vlp
produc
addit
nucleoprotein
np
threecompon
vlp
test
cynomolgu
macaqu
three
intramuscular
inject
mg
mvlp
ml
adjuv
interv
anim
protect
lethal
challeng
plaqueform
unit
pfu
marv
musok
marv
ravv
recent
dye
colleagu
show
mvlp
poli
c
adjuv
also
protect
aerosol
challeng
marv
nhp
gener
broadli
protect
immun
sever
divers
marv
strain
vlp
system
offer
promis
candid
vaccin
human
similar
result
achiev
ebov
vaccin
use
vlp
consist
np
gp
essenti
compon
produc
ebola
vlp
evlp
gp
np
often
ad
evlp
product
sever
studi
shown
npspecif
antibodi
protect
rodent
lethal
ebov
challeng
warfield
colleagu
achiev
complet
protect
lethal
ebov
challeng
pfu
nhp
three
intramuscular
inject
space
day
apart
administ
lg
evlp
includ
ml
ribi
adjuv
challeng
anim
surviv
clinic
sign
observ
addit
viremia
could
detect
time
point
plaqu
assay
studi
adjuv
greatli
reduc
necess
provid
higher
dose
evlp
time
challeng
vaccin
complet
warfield
colleagu
shown
encourag
result
ebov
marv
vaccin
nhp
use
mammalian
insect
cellderiv
vlp
attempt
produc
panfiloviru
vaccin
unabl
provid
consist
protect
heterolog
challeng
attempt
produc
hybrid
vlp
contain
gp
marv
ebov
success
provid
protect
lethal
challeng
either
viru
hybrid
vlp
gp
import
provid
protect
homolog
viru
challeng
howev
boost
strategi
increas
heterolog
antibodi
respons
administr
addit
dose
vlp
mixtur
may
abl
provid
efficaci
panfiloviru
vaccin
consid
fairli
easi
product
vlp
mammalian
insect
cell
line
impress
safeti
profil
along
similar
morpholog
antigen
wildtyp
virus
absenc
preexist
antivector
immun
extens
research
shown
abil
produc
innat
humor
cellular
immun
shown
safe
administ
human
vlp
promis
vaccin
platform
prevent
fhf
outbreak
similar
vlp
system
viruslik
replicon
particl
vrp
system
typic
gener
use
either
flaviviru
alphaviru
vector
gener
replicationincompet
particl
delet
key
structur
protein
limit
infect
vrp
one
cycl
major
research
concern
vrp
vaccin
ebov
marv
infect
focus
use
venezuelan
equin
enceph
viru
veev
alphaviru
vector
replicon
system
veev
use
produc
protein
interest
antigen
place
structur
protein
replicon
vector
thu
gener
selfrepl
rna
molecul
addit
encod
protein
necessari
rna
replic
result
vrp
infect
cell
one
cycl
absenc
veev
structur
protein
inhibit
product
progeni
viru
infect
cell
produc
ampl
amount
desir
protein
marv
ebov
antigen
insert
vrp
typic
gp
target
major
neutral
antibodi
filovir
infect
howev
ebov
protein
examin
past
antigen
use
system
found
inde
gp
could
provid
complet
protect
context
vrp
system
vrp
system
base
veev
describ
hevey
colleagu
one
earlier
vaccin
platform
show
complet
protect
marv
nhp
subsequ
test
multipl
replicon
express
variou
marv
protein
first
assess
guinea
pig
vaccin
vrp
encod
antigen
marv
virion
protein
vp
well
gpdtm
result
partial
protect
degre
efficaci
gp
np
similar
studi
vrp
express
ebov
test
comparison
ebov
gp
np
mice
ebov
gp
np
antigen
could
confer
protect
promis
result
veev
replicon
express
gp
np
warrant
efficaci
studi
use
nhp
model
cynomolgu
macaqu
expos
higher
dose
replicon
express
gp
np
combin
threedos
vaccin
schedul
anim
challeng
pfu
marv
musok
wherein
anim
vaccin
vrpgp
alon
combin
vrpnp
surviv
minim
clinic
sign
diseas
vrpnp
nearli
efficaci
one
three
nhp
succumb
ill
two
survivor
show
clinic
symptom
rang
mild
sever
diseas
herbert
colleagu
publish
promis
result
use
singl
dose
veev
replicon
nhp
updat
vaccin
bival
ebov
sudan
viru
sudv
anoth
speci
genu
ebolaviru
studi
six
cynomolgu
macaqu
intramuscularli
inject
combin
ffu
vrpsudv
bonifac
gp
vrpebov
kikwit
gp
two
group
three
monkey
challeng
either
pfu
either
ebov
sudv
vaccin
macaqu
show
clinic
sign
diseas
protect
initi
challeng
ebov
sudv
respect
six
surviv
anim
backchalleng
heterolog
viru
pfu
day
initi
lethal
viral
challeng
nhp
backchalleng
ebov
surviv
without
develop
clinic
sign
diseas
howev
anim
backchalleng
sudv
develop
diseas
anim
surviv
data
present
herbert
colleagu
demonstr
abil
vrpebov
gp
confer
crossprotect
sudv
vrpsudv
gp
insuffici
provid
complet
protect
ebov
challeng
abil
vrp
platform
crossprotect
sudv
ebov
promis
two
virus
caus
largest
number
human
ebolaviru
infect
one
first
success
vaccin
strategi
provid
full
protect
nhp
dna
vaccin
conjunct
viru
gene
recombin
adenoviru
vector
even
progress
phase
clinic
trial
dna
vaccin
sever
benefit
safe
use
easi
produc
hostcel
protein
synthesi
allow
endogen
present
desir
antigen
final
dna
provid
vaccin
induc
immunestimulatori
respons
previou
studi
use
dna
vaccin
express
ebov
gp
rodent
result
humor
cellmedi
immun
respons
correl
surviv
lethal
challeng
antibodi
titer
underlin
import
humor
immun
respons
protect
ebov
challeng
immunogen
dna
vaccin
improv
use
dna
prime
follow
viral
vector
boost
preliminari
mous
studi
prime
dna
boost
replicationincompet
adenovir
ad
vector
express
ebov
gp
adgp
z
increas
antibodi
titer
fold
compar
dna
vaccin
alon
result
follow
nhp
studi
anim
immun
three
multicompon
dna
inject
four
week
apart
follow
addit
adgp
z
boost
sever
month
later
infect
lethal
dose
ebov
occur
three
month
final
vaccin
vaccin
macaqu
surviv
challeng
show
clinic
sign
diseas
detect
viremia
even
examin
six
month
challeng
encourag
result
led
phase
clinic
trial
adult
complet
vaccin
schedul
show
tcell
respons
well
antibodi
direct
ebov
gp
np
antigen
vaccin
well
toler
deem
safe
detail
report
trial
found
elsewher
recent
novel
approach
use
codonoptim
dna
plasmid
electropor
vaccin
shown
surviv
nhp
two
separ
experi
describ
efficaci
dna
vaccin
marv
infect
use
express
plasmid
marv
gp
nhp
vaccin
three
time
onemonth
interv
dna
express
either
marv
musok
gp
partial
protect
achiev
lethal
challeng
marv
anim
succumb
mhf
anim
show
clinic
sign
diseas
seven
ten
day
challeng
studi
first
report
efficaci
data
vaccin
marv
challeng
nhp
lack
complet
protect
diseas
leav
room
improv
vaccin
studi
publish
sever
year
later
show
greater
efficaci
protect
marv
challeng
nhp
use
dna
vaccin
combin
recombin
vector
deliveri
express
dna
plasmid
contain
marv
gp
recent
marv
outbreak
angola
improv
codon
optim
addit
enhanc
promotor
regulatori
element
describ
previous
increas
protein
express
therefor
immun
respons
vaccin
either
dna
boost
alon
protect
anim
fatal
diseas
challeng
lethal
dose
marv
angola
none
anim
develop
marv
angola
viremia
combin
group
well
dna
group
develop
mild
clinic
sign
rash
lymphocyt
deplet
anorexia
result
describ
geisbert
colleagu
provid
insight
import
tcell
respons
qualit
differ
tcell
respons
seem
correl
protect
nhp
mortal
morbid
use
dna
andor
vaccin
wherea
antigenspecif
antibodi
alon
suffici
protect
mhf
consider
amount
research
conduct
use
recombin
ad
vector
vaccin
strategi
prevent
filoviru
infect
briefli
mention
use
adbas
vector
success
prevent
diseas
mortal
ebov
marv
infect
nhp
sever
ad
vector
strategi
propos
order
increas
immun
potenti
howev
recent
group
updat
previou
vaccin
express
gp
recent
outbreak
strain
ebovmakona
demonstr
protect
efficaci
guinea
pig
nhp
concern
preexist
immun
relat
vector
address
studi
effort
circumv
preexist
vector
immun
human
ad
vector
particularli
human
vector
wide
success
use
preclin
studi
ebov
vaccin
roy
colleagu
design
chimer
ad
vector
express
two
separ
chimpanze
ad
vaccin
complet
protect
mice
lethal
challeng
nhp
immunogen
data
present
public
chimer
chimpanze
vector
yield
magnitud
tcell
activ
rhesu
macaqu
compar
human
therefor
still
develop
stage
anoth
group
attempt
bypass
preexist
immun
human
vector
select
human
shown
one
scarc
neutral
adenovirus
human
serum
sampl
collect
sever
distinct
geograph
region
contrast
select
abil
evad
preexist
immun
proofofconcept
geisbert
colleagu
demonstr
advgp
z
vector
longer
protect
nhp
lethal
ebov
infect
anim
expos
express
transgen
prior
vaccin
challeng
recombin
ebov
gp
test
individu
assess
potenc
immun
respons
induc
neutral
antibodi
respons
vaccin
neither
vector
alon
could
protect
nhp
lethal
challeng
ebov
vaccin
dose
increas
rang
particl
either
vector
partial
surviv
achiev
last
experi
nhp
vaccin
particl
z
gp
sudv
gulu
boost
one
month
later
particl
z
antibodi
titer
specif
gp
well
tcell
respons
significantli
increas
postboost
vector
result
complet
protect
mortal
morbid
lethal
ebov
challeng
vector
togeth
modifi
vaccinia
ankara
express
filoviru
antigen
mvabnfilo
use
uk
phase
clinic
trial
demonstr
good
safeti
immunogen
humor
immun
respons
last
month
anoth
group
look
intranasalairway
deliveri
human
vector
circumv
preexist
immun
codonoptim
ebov
gp
express
second
gener
vector
adcagoptzgp
deliv
intramuscularli
im
intranas
intratrach
either
nhp
ifu
adcagoptzgp
use
combin
pfu
adifna
ad
vector
express
interferon
ifna
act
antivir
adjuv
challeng
lethal
dose
ebov
im
vaccin
nhp
surviv
contrast
im
vaccin
nhp
succumb
ebov
infect
init
vaccin
rout
fulli
protect
nhp
surviv
howev
init
vaccin
nhp
protect
lethal
diseas
encourag
data
demonstr
import
rout
vaccin
administr
efficaci
swenson
colleagu
develop
complex
ad
cadvax
system
express
multipl
antigen
ebov
marv
attempt
gener
panfiloviru
vaccin
cadvax
system
express
follow
filoviru
antigen
ebov
gp
ebov
np
sudv
gp
marv
np
two
marv
gp
musok
ravv
gp
filoviru
np
incorpor
system
describ
increas
cellmedi
immun
respons
sever
construct
express
differ
combin
antigen
mention
gener
express
two
copi
ebov
np
express
marv
gp
ravv
gp
contain
marv
gp
musok
marv
np
express
sudv
gp
ebov
gp
nhp
vaccin
twice
day
pfu
cadvaxpanfilo
vaccin
contain
pfu
separ
two
group
group
challeng
lethal
dose
marv
wherea
group
infect
lethal
dose
ebov
nhp
group
surviv
without
develop
sign
diseas
includ
detect
viremia
order
assess
potenc
panfiloviru
vaccin
two
group
backchalleng
heterolog
speci
filoviru
ten
week
initi
marv
challeng
group
challeng
lethal
dose
sudv
similar
manner
ebov
survivor
group
infect
lethal
dose
marv
backchalleng
result
protect
diseas
fatal
outcom
anim
sever
studi
show
crossreact
antibodi
ebov
marv
indic
inde
panfiloviru
vaccin
confer
protect
differ
filoviru
challeng
newest
approach
involv
adbas
vector
protect
ebov
challeng
develop
stanley
colleagu
vaccin
base
chimpanze
express
ebov
gp
shown
complet
protect
lethal
ebov
infect
nhp
without
limit
preexist
immun
chad
vector
vaccin
acceler
human
phase
clinic
trial
ebola
viru
epidem
west
africa
vaccin
well
toler
particip
antibodi
titer
human
reach
similar
level
observ
nhp
protect
ehf
concern
factor
durabl
protect
immun
respons
antibodi
titer
vaccin
start
drop
month
vaccin
order
circumv
boost
vaccin
mvabnfilo
implement
strategi
improv
immunogen
previous
shown
protect
nhp
strategi
first
test
human
phase
clinic
trial
mali
promis
result
longterm
durabl
data
avail
yet
pfu
ebov
day
last
vaccin
result
anim
succumb
diseas
day
post
challeng
without
protect
efficaci
nhp
vaccin
approach
longer
regard
viabl
vaccin
option
ehf
cytomegaloviru
cmv
base
vaccin
vector
develop
potenti
use
wildlif
immun
strategi
like
herpesvirus
cmv
strictli
speciesspecif
dissemin
vaccin
platform
spread
vaccin
anim
entir
popul
establish
persist
infect
host
strict
speciesspecif
cmv
great
safeti
benefit
platform
anim
human
speci
speci
transmiss
unlik
ebov
np
shown
act
protect
antigen
context
mous
cmv
vaccin
mice
proofofconcept
studi
nhp
need
demonstr
potenti
platform
wildlif
vaccin
eg
ape
africa
therefor
recent
studi
recombin
rhesu
macaqu
cmv
rhcmv
express
codonoptim
ebov
gp
optzgp
use
primeboost
vaccin
scheme
rhesu
macaqu
vaccin
rhcmvebov
gp
suffici
protect
macaqu
lethal
ehf
surviv
anim
show
mild
clinic
sign
diseas
total
antigenspecif
igg
correl
surviv
despit
lack
complet
protect
vaccin
platform
great
potenti
dissemin
wildlif
vaccin
among
anim
speci
thought
introduc
ehf
human
popul
eg
bat
great
ape
develop
recombin
rabi
viru
rabv
vaccin
provid
yet
anoth
potenti
platform
use
human
anim
speci
protect
ehf
blaney
colleagu
develop
replicationcompet
defici
rabv
vector
express
ebov
gp
antigen
protect
ehf
vector
design
hope
bival
vaccin
protect
rabi
ehf
rabv
kill
estim
peopl
yearli
africa
vaccin
could
protect
two
lifethreaten
diseas
africa
highli
desir
rabv
vector
regard
safe
efficaci
vaccin
provid
immun
hiv
sarscov
hepat
c
viru
parent
rabv
strain
use
gener
recombin
vaccin
sad
attenu
effect
use
wildlif
vaccin
therefor
platform
seem
good
approach
prevent
rabv
ehf
human
atrisk
anim
popul
sever
rabvbas
ebov
vaccin
vector
shown
protect
mice
next
step
three
differ
rabv
vector
test
efficaci
ehf
nhp
singl
dose
rabv
ebov
gp
singl
dose
bnspdggp
rabv
ebov
gp
place
gp
two
dose
inactiv
particl
one
dose
replicationcompet
vector
abl
fulli
protect
nhp
lethal
ehf
challeng
day
immun
two
rabv
vector
protect
nhp
lethal
ebov
infect
author
found
antibodi
critic
protect
provid
evid
antibodi
class
particular
seem
matter
order
improv
protect
efficaci
platform
codonoptim
ebov
gp
insert
achiev
increas
antigen
express
two
dose
inactiv
version
vaccin
administ
adjuv
nhp
nhp
protect
low
dose
challeng
pfu
ebov
despit
challeng
dose
lower
major
nhp
challeng
studi
protect
efficaci
rabv
vaccin
platform
encourag
recent
vaccin
oral
given
captiv
chimpanze
result
good
immunogen
data
underlin
potenti
use
wildlif
vaccin
addit
clinic
trial
grade
vaccin
product
current
ongo
human
clinic
trial
hope
start
soon
human
parainfluenza
type
recombin
vaccin
vector
belong
paramyxovirida
famili
provid
abil
intranas
topic
respiratori
tract
vaccin
effect
induc
system
mucos
immun
respons
replic
within
superfici
layer
respiratori
epithelium
typic
dissemin
past
respiratori
tract
appli
intranas
vaccin
diseas
ehf
intrigu
concept
induc
mucos
immun
would
provid
addit
protect
event
bioterror
attack
singledos
vaccin
administ
intranasalintratrach
recombin
vector
express
ebov
gp
ebov
gp
np
ebov
gp
human
cytokin
adjuv
gmcsf
partial
protect
nhp
lethal
ebov
challeng
day
post
immun
one
two
anim
vaccin
gp
np
succumb
diseas
day
post
challeng
contrast
anim
vaccin
gp
gp
gmcsf
protect
lethal
diseas
mild
symptom
fever
observ
group
second
studi
compar
protect
efficaci
singl
vs
two
dose
gp
vaccin
nhp
two
vaccin
dose
protect
nhp
morbid
mortal
wherea
sign
diseas
surviv
record
singl
dose
vaccin
administ
recent
anoth
group
develop
similar
product
express
ebov
gp
intranas
applic
show
immunogen
african
green
monkey
howev
challeng
data
provid
furthermor
aerosol
gp
vaccin
test
shown
provid
full
protect
lethal
ehf
singledos
vaccin
challeng
day
post
immun
induct
strong
system
igg
iga
respons
specif
ebov
gp
mark
vaccin
platform
effect
recombin
vector
protect
ehf
furthermor
tcell
respons
induc
primarili
lung
seemingli
contribut
protect
lethal
ehf
protect
ebov
infect
aerosol
vaccin
repres
noninvas
way
effici
vaccin
deliveri
would
add
reduct
outbreak
potenti
well
prevent
immun
natur
bioterror
threat
one
promis
vaccin
strategi
ehf
mhf
base
recombin
vesicular
stomat
viru
rvsv
similar
rabv
vsv
belong
rhabdovirida
famili
contain
negativestrand
rna
genom
encod
five
protein
rose
colleagu
develop
revers
genet
system
vsv
allow
easi
manipul
viru
lead
optim
express
antigen
vector
abil
vsv
grow
high
titer
vivo
well
vitro
mammalian
cell
line
make
easytoproduc
vaccin
addit
vsv
shown
strong
induc
innat
adapt
immun
respons
advantag
properti
vaccin
vector
vsv
natur
infect
livestock
variou
anim
make
infect
human
rare
diseas
often
asymptomat
result
limit
preexist
immun
human
popul
preexist
immun
occur
mainli
direct
vsv
surfac
protein
g
describ
pathogen
factor
viru
order
circumv
complic
presenc
vsv
g
two
approach
explor
first
truncat
g
cytoplasm
domain
mainli
associ
pathogen
second
replac
g
protein
heterolog
viral
surfac
protein
eg
ebov
gp
garbutt
colleagu
describ
gener
rvsv
vector
replac
vsv
g
either
ebov
mayinga
gp
marv
musok
gp
lassa
viru
lasv
josiah
glycoprotein
vsvebov
vector
term
vsvdgebovgp
vsvzebovgp
similar
rest
manuscript
refer
vsvebov
vsvmarv
vsvlasv
jone
colleagu
perform
first
efficaci
studi
use
singl
dose
vsvebov
vsvmarv
vaccin
nhp
fulli
protect
anim
lethal
ebov
marv
challeng
day
vaccin
marv
survivor
rechalleng
relat
marv
popp
strain
day
first
marv
musok
challeng
surviv
observ
contrast
ebovsurviv
nhp
surviv
rechalleng
sudv
day
ebov
challeng
order
overcom
lack
crossprotect
particularli
ebolaviru
speci
vsvebov
vsvsudv
vsvmarv
blend
singledos
vaccin
nhp
surviv
lethal
challeng
day
later
either
tai
forest
viru
tafv
ebov
sudv
marv
respect
studi
demonstr
first
time
potenti
crossprotect
ebolaviru
speci
use
vaccin
platform
tafv
gp
part
vaccin
yet
anim
surviv
lethal
tafv
infect
furthermor
marzi
colleagu
show
recent
consecut
vaccin
vsvlasv
follow
month
later
vsvebov
compromis
immunogen
anim
protect
lethal
lasv
ebov
challeng
number
addit
studi
perform
summar
mechanist
studi
marzi
colleagu
identifi
ebov
gpspecif
antibodi
elicit
vsvebov
critic
protect
wong
associ
shown
rodent
nhp
ebov
gpspecif
serum
igg
level
correl
surviv
recent
studi
demonstr
fastact
potenti
vsvebov
vaccin
ebovmakona
isol
west
african
ebov
epidem
outbreak
strain
nhp
vaccin
day
prior
ebov
challeng
surviv
lethal
challeng
without
develop
diseas
howev
vaccin
administ
day
prior
challeng
nhp
surviv
anim
develop
mild
moder
sever
diseas
respect
addit
vsvebov
second
vsvbase
platform
develop
includ
vsv
g
gene
truncat
cytoplasm
tail
mire
colleagu
demonstr
two
version
novel
vector
express
ebov
gp
protect
viru
gene
nhp
challeng
lethal
dose
ebovmakona
day
singledos
vaccin
neither
clinic
sign
diseas
viremia
observ
anim
preclin
studi
perform
use
rvsv
vaccin
platform
ehf
mhf
nhp
model
support
acceler
vsvebov
clinic
trial
west
african
ebov
epidem
phase
ii
clinic
trial
took
place
worldwid
yield
promis
immunogen
result
despit
concern
sideeffect
highdos
vaccin
particularli
one
cohort
review
howev
encourag
news
result
phase
iii
clinic
trial
guinea
vsvebov
use
ring
vaccin
strategi
stop
ebov
transmiss
control
epidem
studi
show
vsvebov
inde
fastact
vaccin
show
efficaci
day
vaccin
new
case
occur
time
cohort
encourag
data
underlin
great
potenti
vaccin
emerg
use
addit
studi
confirm
nhp
data
present
earlier
valid
nhp
model
gold
standard
ebov
marv
countermeasur
develop
discoveri
filovirus
four
decad
old
one
wonder
still
approv
therapeut
vaccin
avail
human
use
sever
experiment
vaccin
approach
test
ebov
lesser
extent
marv
fig
almost
progress
made
toward
clinic
trial
take
consider
filovirus
handl
high
contain
facil
avail
countri
worldwid
caus
thousand
human
fatal
never
enough
commerci
interest
fund
avail
develop
licens
countermeasur
situat
chang
follow
ebov
epidem
devast
west
africa
trial
promis
countermeasur
approach
acceler
fund
made
avail
licensur
process
almost
one
year
west
africa
declar
free
human
ebov
case
progress
countermeasur
licensur
continu
slow
although
promis
data
phase
iiii
clinic
trial
rais
hope
protocol
establish
least
allow
use
preind
vaccin
treatment
emerg
outbreak
ideal
better
prepar
act
quickli
infecti
diseas
outbreak
start
know
statu
experiment
preind
countermeasur
approach
could
use
emerg
west
african
ebov
epidem
one
devast
exampl
modernday
emerg
infecti
diseas
outbreak
thank
continualalbeit
slowprogress
develop
vaccin
countermeasur
hope
never
repeat
